ACETO Subsidiary, Rising Pharmaceuticals, Launches Generic Version of Soma(R) Compound With Aspirin Tablets and Sodium Bicarbonate Tablets

        Print
| Source: ACETO Corporation

PORT WASHINGTON, N.Y., July 9, 2012 (GLOBE NEWSWIRE) -- ACETO Corporation (Nasdaq:ACET), a global leader in the marketing, sales and distribution of pharmaceutical active ingredients and intermediates, finished dosage form generics, nutraceutical products, agricultural protection products and specialty chemicals, today announced that Rising Pharmaceuticals Inc., its finished dosage form generics subsidiary, has launched the 200mg/325mg strengths of Carisoprodol and Aspirin Tablets, USP, an FDA approved generic version of Meda Pharmaceutical's Soma® Compound with Aspirin Tablets, and 10/gr Sodium Bicarbonate Tablets, USP. According to IMS Health data, U.S. market sales for Carisoprodol and Aspirin Tablets, USP, used to relieve pain, muscle spasm and limited mobility associated with acute painful musculoskeletal conditions, and Sodium Bicarbonate Tablets, USP, an antacid used to relieve heartburn and acid indigestion, were approximately $3.1 million collectively for the twelve months ended December 31, 2011.

ABOUT ACETO

ACETO Corporation, incorporated in 1947, is a global leader in the marketing, sales and distribution of pharmaceutical active ingredients and intermediates, finished dosage form generic pharmaceuticals, nutraceutical products, agricultural protection products and specialty chemicals. With business operations in nine countries, ACETO distributes over 1,100 chemical compounds used principally as finished products or raw materials in the pharmaceutical, nutraceutical, agricultural, coatings and industrial chemical consuming industries. ACETO's global operations, including a staff of 26 in China and 12 in India are distinctive in the industry and enable its worldwide sourcing and regulatory capabilities.

The Aceto Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=13058

This news release contains forward-looking statements as that term is defined in the federal securities laws. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO's reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO's Annual Report or Form 10-K for the fiscal year ended June 30, 2011 and other filings. Copies of these filings are available at http://www.sec.gov/ blocked::http://www.sec.gov/">www.sec.gov.   ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Investor Relations Contact:
Amy Glynn
The Ruth Group
(646) 536-7023